Literature DB >> 9079743

Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer.

E C de Boer1, L Somogyi, G J de Ruiter, T M de Reijke, K H Kurth, D H Schamhart.   

Abstract

In intravesical therapy for superficial bladder carcinoma urothelial cells may, through the production of cytokines, contribute to the bacillus Calmette-Guerin (BCG)-induced local immunological reaction and associated antitumor efficacy. The aim of this study was to investigate such a role for the neutrophil-attracting cytokine interleukin-8 (IL-8). The appearance of IL-8 in patients urine after BCG therapy was compared with BCG-induced IL-6 and IL-2 and the stability of IL-8 in urine was tested. Compared to IL-6 and IL-2, a rapid induction of IL-8 was observed, occurring after the first BCG instillation. Urinary IL-8 was highly stable, even after 24 h incubation at 37 degrees C. The IL-8 concentration after the first instillation seemed to be associated with subsequent development of an immune response. Consequently, IL-8 seems an attractive candidate for investigation of its prognostic value for a clinical response to BCG therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9079743     DOI: 10.1007/bf00941903

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  21 in total

1.  Urinalysis for interleukin-8 in the non-invasive diagnosis of acute and chronic inflammatory diseases.

Authors:  A S Taha; V Grant; R W Kelly
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

Review 2.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 3.  BCG immunotherapy for bladder cancer--the effects of substrain differences.

Authors:  Christine Gan; Hugh Mostafid; Muhammad Shamim Khan; David J M Lewis
Journal:  Nat Rev Urol       Date:  2013-09-17       Impact factor: 14.432

4.  Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment.

Authors:  Sung Hyun Kang; Russ Chess-Williams; Shailendra Anoopkumar-Dukie; Catherine McDermott
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-03       Impact factor: 3.000

5.  High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis.

Authors:  Kai Qu; Jian Gu; Yuanqing Ye; Stephen B Williams; Colin P Dinney; Xifeng Wu; Ashish Kamat
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

6.  Bacillus Calmette Guérin in bladder cancer: is more immune stimulation better?

Authors:  Mar Valés-Gómez
Journal:  Transl Androl Urol       Date:  2019-12

Review 7.  Immunotherapeutic strategies for high-risk bladder cancer.

Authors:  Padmanee Sharma; Lloyd J Old; James P Allison
Journal:  Semin Oncol       Date:  2007-04       Impact factor: 4.929

Review 8.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.

Authors:  Chrysoula I Liakou; Sowmita Narayanan; Derek Ng Tang; Christopher J Logothetis; Padmanee Sharma
Journal:  Cancer Immun       Date:  2007-06-26

Review 9.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

10.  Dr William Coley and tumour regression: a place in history or in the future.

Authors:  S A Hoption Cann; J P van Netten; C van Netten
Journal:  Postgrad Med J       Date:  2003-12       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.